Lipoprotein(a), interleukin-10, c-reactive protein, and 8-year outcome after percutaneous coronary intervention

Clinical Cardiology

Volumn 35, Issue 8, 2012, Pages 482-489

  Kardys, Isabella ^a   Oemrawsingh, Rohit M ^a   Kay, I Patrick ^b   Jones, Gregory T ^c   McCormick, Sally P A ^c   Daemen, Joost ^a   Van Geuns, Robert Jan ^a   Boersma, Eric ^a   Van Domburg, Ron T ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Mercy Angiography Unit   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYPHER; INTERLEUKIN 10; LIPOPROTEIN A; RAPAMYCIN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; LIMIT OF DETECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; PROSPECTIVE STUDY; STABLE ANGINA PECTORIS; STATISTICAL SIGNIFICANCE; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CONFIDENCE INTERVALS; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; INTERLEUKIN-10; LIPOPROTEIN(A); MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK ASSESSMENT; TIME FACTORS;

EID: 84864654878     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.21988     Document Type: Article

References (32)

1. Garg S, Serruys PW., Coronary stents: current status. J Am CollCardiol. 2010; 56: S1-S42.
2. Koenig W, Khuseyinova N., Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc Drugs Ther. 2009;23: 85-92.
3. Morrow DA, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007;115: e356-e375.
4. Jaffe AS, Babuin L, Apple FS., Biomarkers in acute cardiac disease: the present and the future. J Am CollCardiol. 2006; 48: 1-11. (Pubitemid 44202476)
5. Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P., New risk factors for atherosclerosis and patient risk assessment. Circulation. 2004;109: III15-III19. (Pubitemid 38786438)
6. Girndt M, Kohler H., Interleukin-10 (IL-10): an update on its relevance for cardiovascular risk. Nephrol Dial Transplant. 2003; 18: 1976-1979. (Pubitemid 37220299)
7. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation. 2004;109: 190-195.
8. Jones GT, van Rij AM, Cole J, et al. Plasma lipoprotein(a) indicates risk for 4 distinct forms of vascular disease. Clin Chem. 2007; 53: 679-685. (Pubitemid 46580238)
9. Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem. 2000; 46: 1956-1967.
10. Delhaye C, Maluenda G, Wakabayashi K, et al. Long-term prognostic value of preprocedural C-reactive protein after drug-eluting stent implantation. Am J Cardiol. 2010;105: 826-832.
11. Iijima R, Byrne RA, Ndrepepa G, et al. Pre-proceduralC-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials. Heart 2009; 95: 107-112.
12. Razzouk L, Muntner P, Bansilal S, et al. C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention. Am Heart J. 2009; 158: 277-283.
13. Gach O, Legrand V, Biessaux Y, et al. Long-term prognostic significance of high-sensitivity C-reactive protein before and after coronary angioplasty in patients with stable angina pectoris. Am J Cardiol. 2007;99: 31-35.
14. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010; 31: 2844-2853.
15. Alaigh P, Hoffman CJ, Korlipara G, et al. Lipoprotein(a) level does not predict restenosis after percutaneous transluminal coronary angioplasty. ArteriosclerThrombVasc Biol. 1998; 18: 1281-1286. (Pubitemid 28376185)
16. Cooke T, Sheahan R, Foley D, et al. Lipoprotein(a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease. Circulation. 1994;89: 1593-1598.
17. Desmarais RL, Sarembock IJ, Ayers CR, et al. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation. 1995;91: 1403-1409.
18. Gazzaruso C, Garzaniti A, Falcone C, et al. Restenosis after intracoronary stent placement: can apolipoprotein(a) polymorphism play a role? Int J Cardiol. 2003;87: 91-98.
19. Miyata M, Biro S, Arima S, et al. High serum concentration of lipoprotein(a) is a risk factor for restenosis after percutaneous transluminal coronary angioplasty in Japanese patients with single-vessel disease. Am Heart J. 1996;132: 269-273.
20. Ribichini F, Steffenino G, Dellavalle A, et al. Plasma lipoprotein(a) is not a predictor for restenosis after elective high-pressure coronary stenting. Circulation. 1998;98: 1172-1177.
21. Wehinger A, Kastrati A, Elezi S, et al. Lipoprotein(a) and coronary thrombosis and restenosis after stent placement. J Am CollCardiol. 1999; 33: 1005-1012.
22. Zairis MN, Ambrose JA, Manousakis SJ, et al. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am CollCardiol.2002; 40: 1375-1382. (Pubitemid 35192859)
23. Igarashi Y, Aizawa Y, Satoh T, et al. Predictors of adverse long-term outcome in acute myocardial infarction patients undergoing primary percutaneous transluminal coronary angioplasty: with special reference to the admission concentration of lipoprotein (a). Circ J. 2003; 67: 605-611. (Pubitemid 36834389)
24. Rahel BM, Visseren FL, Suttorp MJ, et al. Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention. Cardiovasc Res. 2003; 60: 136-140. (Pubitemid 38373484)
25. Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res. 1999; 85: e17-e24.
26. Oemrawsingh RM, Lenderink T, Akkerhuis KM, et al. Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome. Heart. 2011;97: 1061-1066.
27. Anguera I, Miranda-Guardiola F, Bosch X, et al. Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. Am Heart J. 2002; 144: 811-817. (Pubitemid 35335172)
28. Chang LT, Yuen CM, Sun CK, et al. Role of stromal cell-derived factor-1alpha, level and value of circulating interleukin-10 and endothelial progenitor cells in patients with acute myocardial infarction undergoing primary coronary angioplasty. Circ J 2009; 73: 1097-1104.
29. Heeschen C, Dimmeler S, Hamm CW, et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation. 2003;107: 2109-2114.
30. Yip HK, Youssef AA, Chang LT, et al. Association of interleukin-10 level with increased 30-day mortality in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention. Circ J. 2007;71: 1086-1091.
31. Ezhov MV, Sumarokov AB, RaimbekovaIR, Masenko VP, Naumov VG. Interleukin 6 but not interleukin 10 is associated with restenosis after coronary stenting. Atherosclerosis. 2003;169: 193-194. (Pubitemid 36830939)
32. Zurakowski A, Wojakowski W, Dzielski T, et al. Plasma levels of C-reactive protein and interleukin-10 predict late coronary in-stent restenosis 6 months after elective stenting. Kardiol Pol. 2009; 67: 623-630.